122 related articles for article (PubMed ID: 404154)
1. Metabolic and clinical studies on patients with acromegaly treated with bromocriptine over 22 months.
Schwinn G; Dirks H; McIntosh C; Köbberling J
Eur J Clin Invest; 1977 Apr; 7(2):101-7. PubMed ID: 404154
[TBL] [Abstract][Full Text] [Related]
2. [Therapy of acromegaly using bromocriptine].
Köbberling J; Schwinn G; Dirks H
Dtsch Med Wochenschr; 1975 Jul; 100(29):1540-2. PubMed ID: 1149634
[TBL] [Abstract][Full Text] [Related]
3. Bromocriptine treatment of acromegaly.
Cassar J; Mashiter K; Joplin GF
Metabolism; 1977 May; 26(5):539-46. PubMed ID: 576725
[TBL] [Abstract][Full Text] [Related]
4. Changes in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests.
Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F
Acta Endocrinol (Copenh); 1984 Jun; 106(2):175-83. PubMed ID: 6145276
[TBL] [Abstract][Full Text] [Related]
5. No acute effect of pimozide on the plasma GH levels in acromegaly.
Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F
Acta Endocrinol (Copenh); 1983 Aug; 103(4):461-8. PubMed ID: 6613492
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue.
Yang IM; Woo JT; Kim SW; Kim JW; Kim YS; Choi YK
Clin Endocrinol (Oxf); 1995 Mar; 42(3):295-301. PubMed ID: 7758235
[TBL] [Abstract][Full Text] [Related]
7. Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly.
Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Liuzzi A; Chiodini PG
J Clin Endocrinol Metab; 1986 Mar; 62(3):601-4. PubMed ID: 3080469
[TBL] [Abstract][Full Text] [Related]
8. Bromocriptine therapy in acromegaly.
Sachdev Y; Gomez-Pan A; Tunbridge WM; Duns A; Weightman DR; Hall R; Goolamali SK
Lancet; 1975 Dec; 2(7946):1164-8. PubMed ID: 53655
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states.
Verde G; Chiodini PG; Liuzzi A; Cozzi R; Favales F; Botalla L; Spelta B; Dalla Bonzana D; Rainer E; Horowski R
J Endocrinol Invest; 1980; 3(4):405-14. PubMed ID: 6782153
[TBL] [Abstract][Full Text] [Related]
10. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
[TBL] [Abstract][Full Text] [Related]
11. The combination therapy with bromocriptine and cyproheptadine in patients with acromegaly.
Hanew K; Sugawara A; Shimizu Y; Sato S; Sasaki A; Tazawa S; Ishii K; Saitoh T; Saso S; Yoshinaga K
Endocrinol Jpn; 1989 Jun; 36(3):429-38. PubMed ID: 2510991
[TBL] [Abstract][Full Text] [Related]
12. Effect of different dopaminergic agents in the treatment of acromegaly.
Colao A; Ferone D; Marzullo P; Di Sarno A; Cerbone G; Sarnacchiaro F; Cirillo S; Merola B; Lombardi G
J Clin Endocrinol Metab; 1997 Feb; 82(2):518-23. PubMed ID: 9024247
[TBL] [Abstract][Full Text] [Related]
13. Differential response to aminergic stimuli and biological behavior of growth hormone secreting pituitary adenomas.
Fanghanel G; Larraza O; Villalobos M; Fanghanel L; Velasco M; Velasco F
Can J Neurol Sci; 1990 Feb; 17(1):78-82. PubMed ID: 2107017
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of acromegaly with bromocryptine: postprandial HGH levels and response to TRH and glucose administration.
Benker G; Zäh W; Hackenberg K; Hamburger B; Günnewig H; Reinwein D
Horm Metab Res; 1976 Jul; 8(4):291-5. PubMed ID: 182633
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutical effects of bromocriptine (CB 154) in 10 acromegalic subjects. Study of somatotrophic function and clinical survey (author's transl)].
Fossati P; Asfour M; Brion-Brevan B; Fourlinnie JC; Cappoen JP; Dalle-Furnari MA; Blacker C
Ann Endocrinol (Paris); 1977; 38(4):291-301. PubMed ID: 332054
[TBL] [Abstract][Full Text] [Related]
16. Bromocriptine treatment over 12 years in acromegaly: effect on growth hormone and prolactin secretion.
Rau H; Althoff PH; Schmidt K; Usadel KH
Acta Endocrinol (Copenh); 1992 Mar; 126(3):247-52. PubMed ID: 1574954
[TBL] [Abstract][Full Text] [Related]
17. Bioactive GH-like immunoglobulins G in active acromegaly: response to long-term treatment with bromocriptine.
Campino C; Szecowka J; Lopez JM; Seron-Ferre M
Clin Endocrinol (Oxf); 1995 Jul; 43(1):111-6. PubMed ID: 7641402
[TBL] [Abstract][Full Text] [Related]
18. Plasma growth hormone suppressive effect of bromocriptine in acromegaly. Evaluation by plasma GH day profiles and plasma GH concentrations during oral glucose tolerance tests.
Nortier JW; Croughs RJ; Thijssen JH; Schwarz F
Clin Endocrinol (Oxf); 1984 May; 20(5):565-71. PubMed ID: 6744634
[TBL] [Abstract][Full Text] [Related]
19. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
Barkan AL; Kelch RP; Hopwood NJ; Beitins IZ
J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720
[TBL] [Abstract][Full Text] [Related]
20. Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humans.
Liuzzi A; Chiodini PG; Oppizzi G; Botalla L; Verde G; De Stefano L; Colussi G; Gräf KJ; Horowski R
J Clin Endocrinol Metab; 1978 Feb; 46(2):196-202. PubMed ID: 108287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
